Key facts
- Tissue Dynamics identified a new metabolic pathway for cardiac fibrosis and heart failure.
- The discovery was made using human cardiac organoid models.
- This pathway is not accessible through conventional animal models.
- The findings support the development of Galmed's drug Aramchol for cardiac fibrosis.
Tissue Dynamics has identified a previously unrecognized metabolic mechanism that drives cardiac fibrosis and heart failure. This breakthrough was achieved using human cardiac organoid models, offering insights into disease biology that are not obtainable through traditional animal models. The discovery is significant as it directly supports the ongoing development of Galmed's drug, Aramchol, for the treatment of cardiac fibrosis.